Breaking News

Wednesday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
ADVM Adverum Biotechnologies $5.04 -0.19 (-3.63%) , EDIT Editas Medicine $29.60 0.49 (1.68%) 16:14 10/17/18 10/17 16:14 10/17/18 16:14 Hot Stocks	Adverum Biotechnologies promotes Leone Patterson to CEO » Adverum Biotechnologies… Adverum Biotechnologies (ADVM) announced the promotion of Leone Patterson as the company's president and CEO. Patterson has served as Adverum Biotechnologies' interim president and CEO since May 3. Patterson was also named to the Adverum Biotechnologies board as a director. Patterson joined Adverum Biotechnologies in June of 2016 as the company's CFO and has been acting as interim president and CEO since May. Patterson will continue to serve as the company's CFO until a new CFO is hired. During her tenure, Adverum entered into a collaboration with Editas Medicine (EDIT) to explore genome editing medicines to the eye, closed a $69M public offering, and advanced the development of its gene therapy pipeline. ADVM Adverum Biotechnologies $5.04 -0.19 (-3.63%) EDIT Editas Medicine $29.60 0.49 (1.68%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
EDIT Editas Medicine $27.76 -0.13 (-0.47%) 16:34 10/09/18 10/09 16:34 10/09/18 16:34 Initiation	Editas Medicine initiated at Guggenheim » Editas Medicine initiated… Editas Medicine initiated with a Neutral at Guggenheim. Guggenheim analyst Whitney Ijem initiated Editas Medicine with a Neutral rating, calling the company's potential "mostly theoretical at this point as the company has yet to identify programs where these assets can be uniquely deployed." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Oct
EDIT Editas Medicine $27.53 -1 (-3.51%) , NTLA Intellia Therapeutics $23.99 -0.39 (-1.60%) … 11:59 10/08/18 10/08 11:59 10/08/18 11:59 Periodicals	Scientists use CRISPR to cure mice disorder in womb, STAT reports » Scientists reported today… Scientists reported today that they used CRISPR to alter the DNA of laboratory mice in the womb, eliminating a deadly liver disease before the animals had even been born, Sharon Begley of STAT reports. CRISPRing human fetuses is still years away, but the success in mice paves the way for curing genetic diseases before birth, the writer adds. Companies developing CRISPR-based therapies include Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Crispr Therapeutics (CRSP). Reference Link EDIT Editas Medicine $27.53 -1 (-3.51%) NTLA Intellia Therapeutics $23.99 -0.39 (-1.60%) CRSP Crispr Therapeutics $36.37 -2.18 (-5.66%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Oct
EDIT Editas Medicine $29.00 -1.245 (-4.12%) 10:25 10/04/18 10/04 10:25 10/04/18 10:25 Conference/Events	Editas Medicine participates in a conference call with JPMorgan » JPMorgan Large Cap… JPMorgan Large Cap Biotech Analyst Kasimov hosts a conference call with CEO Bosley on October 4 at 11 am. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	04 Oct
EDIT Editas Medicine $30.24 1.11 (3.81%) 04:55 10/04/18 10/04 04:55 10/04/18 04:55 Conference/Events	Editas Medicine participates in a conference call with JPMorgan » JPMorgan Large Cap… JPMorgan Large Cap Biotech Analyst Kasimov hosts a conference call with CEO Bosley on October 4 at 11 am. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	04 Oct

EDIT Editas Medicine $30.09 -0.39 (-1.28%) 10:19 10/02/18 10/02 10:19 10/02/18 10:19 Conference/Events	Editas Medicine participates in a conference call with JPMorgan » JPMorgan Large Cap… JPMorgan Large Cap Biotech Analyst Kasimov hosts a conference call with CEO Bosley on October 4 at 11 am. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Oct 04 Oct
EDIT Editas Medicine $32.55 -0.64 (-1.93%) 07:45 09/21/18 09/21 07:45 09/21/18 07:45 Initiation	Editas Medicine initiated at Raymond James » Editas Medicine initiated… Editas Medicine initiated with an Outperform at Raymond James. Raymond James analyst Steven Seedhouse initiated Editas Medicine with an Outperform and $40 price target saying data comps for lead indication LCA10 are the easiest, and is the best lead indication of the three CRISPR pure plays. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
EDIT Editas Medicine $32.55 -0.64 (-1.93%) 16:43 09/20/18 09/20 16:43 09/20/18 16:43 Initiation	Editas Medicine initiated at Raymond James » Editas Medicine initiated… Editas Medicine initiated with an Outperform at Raymond James 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
SGMO Sangamo $14.60 0.85 (6.18%) , EDIT Editas Medicine $31.03 0.77 (2.54%) … 16:05 09/10/18 09/10 16:05 09/10/18 16:05 Periodicals	Study finds rolled up genes can't be edited by CRISPR, STAT reports » A scientific study found… A scientific study found that rolled up genes in a hedgehog cannot be cut by CRISPR-Cas9, according to STAT. If CRISPR "can't see DNA when it's wrapped around a nucleosome," said biochemist Dana Carroll of the University of Utah, who led the study, "it could be an issue." Companies developing CRISPR-based therapies include Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Crispr Therapeutics (CRSP). The previous generation genome editor, called zinc fingers, had no problem reaching DNA that's wrapped around nucleosomes, Carroll's team reported, according to STAT. Sangamo Therapeutics (SGMO), who Carroll receives license royalties from, is betting on zinc fingers rather than CRISPR, the article points out. Shares of Sangamo closed the trading day up 90c to $14.65. Reference Link SGMO Sangamo $14.60 0.85 (6.18%) EDIT Editas Medicine $31.03 0.77 (2.54%) CRSP Crispr Therapeutics $49.58 -0.61 (-1.22%) NTLA Intellia Therapeutics $26.97 -0.26 (-0.95%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Sep 27 Sep
EDIT Editas Medicine $30.49 0.23 (0.76%) 14:18 09/10/18 09/10 14:18 09/10/18 14:18 Hot Stocks	Editas 'pleased' U.S. appeals court affirmed favorable USPTO decision » Editas Medicine announced… Editas Medicine announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. Patent and Trademark Office decision that ended the U.S. patent interference between the University of California, the University of Vienna, and Emmanuelle Charpentier and the Broad Institute, Inc. concerning certain CRISPR/Cas9 patents Editas Medicine exclusively licenses from Broad. This favorable action by the CAFC upholds the USPTO decision issued in February 2017, granting Broad's motion for no interference-in-fact. "We are pleased with the Federal Circuit's decision affirming the Patent Trial and Appeal Board decision on the patents that were granted to the Broad Institute for its innovative and fundamental work on CRISPR/Cas9 genome editing," said Katrine Bosley, President and Chief Executive Officer, Editas Medicine. "This decision is highly favorable for Editas and for the Broad as it reaffirms the strength of our intellectual property foundation and has profound implications for making CRISPR medicines." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Sep

On The Fly

News and insights, exclusive to thefly.com

16:09	On The Fly: Weekly technical notes for S&P 500»
16:07	Fly Intel: Wall Street's top stories for Friday»
15:44	On The Fly: Weekly technical notes for Russell 2000»
14:33	#SocialStocks: Snap may be small enough to be acquired, YouTube suffers blackout»
13:44	On The Fly: ETF fund flow highlights»

View all On The Fly Stories »

Upcoming
Events (10)

	CFTC Talks: Federal Reserve Bank of Dallas President Kaplan
	South Africa 9th Annual Economics Conference
ABBV ...	2018 ACR/ARHP Annual Meeting
	NIC Fall Conference 2018
	INSIGHTS 2018
JPM ...	17th Macro Quantitative & Derivatives Research Conference
	ASHG Conference 2018
ABBV ...	ESMO 2018 Congress
SNX	Synnex
	Diversified Industrials, Flow Control

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals for your search.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial